Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Coronavirus / COVID-19 Pandemic -- Ignore unavailable to you. Want to Upgrade?

To: B.K.Myers who wrote (6620)	7/29/2020 3:00:11 AM
From: i-node	Read Replies (1) \| Respond to of 22868

Yeah, but these were both duds. Not sure I remember the details on them, but I think the SOLIDARITY trial was cancelled because the withdrawal of an article in The Lancet. There was some kind of fraud issue in the other trial. It was a mess. The other one was of hospitalized patients, which we already knew HCQ didn’t work on so it didn’t provide any new information, iirc. After that patients were not that interested in the trials and they started having difficulty in getting enrollees because people were hearing so much false nonsense about people dying from the treatment. Strangely, one of the clearest bits of proof HCQ works was a result of the stoppage of a trial as a result of the Lancet article. It was very compelling, a simple chart that showed what happened to the fatality rate (maybe in Brazil) when they quit giving HCQ. Fatalities shot up to the levels prior to the beginning of the trial. Then, when they resumed 13 days later, fatalities dropped again. Of course that wasn’t a study but it was compelling proof nevertheless. This is one of the points being made by Dr. Risch, that the idiotic demand that everything has to be a RCT is absurd. Sometimes, there is solid proof outside a RCT and if you have no choice but to let patients die, you’re not doing patients a favor to withhold a safe treatment. I might have posted that graph on this thread but it was extremely evident where the treatment left off and resumed.

To: B.K.Myers who wrote (6620)	7/29/2020 4:37:00 PM
From: Investor2	Respond to of 22868

The original double-blind test of remdesevir showed that remdesevir decreased the length of the hospital stay from 14 days to 11 days but DID NOT improve the death rate of Covid-19 patients. I have seen an unpublished followup to the study by the manufacturer indicating that it was able to get remdesevir to improve the death rate, but I haven't seen a followup of an official reviewed and published study documenting this. Have you seen a finalized study that documented an improvement in the death rate? Thanks, I2